LG Chem: all 184 studies

Page 2 of 2. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.

• A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in AdultsCompletedNCT02892812Phase 1
• Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study)CompletedNCT02831361Phase 3
• Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI PatientsStatus unknownNCT02770664Phase 2
• A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate TherapyCompletedNCT02746380Phase 3
• A Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 in Subjects With Active RA Despite Methotrexate (MTX)CompletedNCT02715908Phase 3
• BE Study of the Combinations of Gemigliptin 50mg and Rosuvastatin 20mg in Comparison to Each Component Administered AloneStatus unknownNCT02670070Phase 1
• BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 2000mg in Comparison to Each Component Administered AloneStatus unknownNCT02670018Phase 1
• Pharmacokinetics and Safety Study of Apetrol ESCompletedNCT02446353Phase 1
• Bioequivalence of a Single Subcutaneous Dose of BEPO and REPO in Healthy Male SubjectsCompletedNCT02426151Phase 1
• Observational Study to Evaluate the Safety and Efficacy for Levacalm Tab. Versus Valsartan/Amlodipine Combination Therapy in Essential Hypertension PatientsStatus unknownNCT02415192
• A Study Comparing LBEC0101 to Enbrel® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate TherapyStatus unknownNCT02357069Phase 3
• An Observational Study to Evaluate Cardiovascular Outcomes of T2DM PatientsTreated With GemigliptinCompletedNCT02290301
• Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization in Infants From 6 WeeksStatus unknownNCT02257645
• Pharmacokinetics and Safety Study of LBAL in Healthy SubjectsCompletedNCT02206867Phase 1
• Study to Assess the Efficacy and Safety of Eutropin in Prader-Willi SyndromeCompletedNCT02204163Phase 3
• Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)CompletedNCT02126358Phase 3
• A Clinical Trial to Evaluate the Safety and Efficacy of Retreatment With Intra-articular LBSA0103 Injections in the Patients With Osteoarthritis of the KneeCompletedNCT02122601Phase 3
• Extension Clinical Study to Evaluate the Long-term Efficacy and Safety of Repeat Treatment of YVOIRE Contour Injected Into the Anteromedial Malar Region in Subjects Who Have Completed the LG-HACL014 StudyCompletedNCT02119793Not applicable
• Clinical Study to Evaluate the Efficacy and Safety of YVOIRE® Contour Compared With Restylane SubQ™ Injected Into the Anteromedial Malar RegionStatus unknownNCT02119780Not applicable
• Protocol to Allow Continued Access of Ficlatuzumab to P05538 PatientNo longer availableNCT02090127
• Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 DiabetesStatus unknownNCT02089126Phase 3
• Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI PatientsCompletedNCT02070471Phase 2
• BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone.CompletedNCT02056600Phase 1
• Efficacy and Safety Study of Sr-hGH in Comparison With Daily hGH in ISS PatientsCompletedNCT02042170Phase 2
• Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White VolunteersCompletedNCT02004587Phase 1
• Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and MetforminCompletedNCT01990469Phase 3
• A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study)CompletedNCT01968044Phase 3
• Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive PatientsCompletedNCT01928628Phase 3
• Drug Interaction and Safety Between Valsartan and Rosuvastatin in Healthy Male VolunteersCompletedNCT01918709Phase 1
• Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan® (Valsartan) Film-coated Tablet 160 mg and Crestor® (Rosuvastatin) 20 mgCompletedNCT01918358Phase 1
• A Phase III Study to Assess the Immunogenicity and Safety of Eutravac (DTap-HB Combined Vaccine) With DTaP and Hepatitis B Vaccines in Healthy InfantsCompletedNCT01896739Phase 3
• Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study)CompletedNCT01890629Phase 4
• Phase I Trial for Pharmacokinetic Characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) With Factive 320mg Tablet Formulation (Gemifloxacin 320mg)CompletedNCT01879007Phase 1
• Pharmacokinetic Drug Interaction Study Between Gemigliptin and Irbesartan After Oral Administration in Healthy Male SubjectsCompletedNCT01825850Phase 1
• Study for Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and RosuvastatinCompletedNCT01823133Phase 1
• To Assess the Anti-adhesive Effect and Safety of ProtescalTerminatedNCT01810900Phase 3
• Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.dCompletedNCT01787396Phase 3
• Pharmacokinetic Drug Interaction Study Between Gemigliptin and Glimepiride in Healthy Male SubjectsCompletedNCT01768455Phase 1
• Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)CompletedNCT01747083Phase 1
• Study to Investigate the Safety and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male SubjectsCompletedNCT01737424Phase 1
• Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25mg With Those of Enbrel®CompletedNCT01725620Phase 1
• Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in CINV (Chemotherapy-induced Nausea and Vomiting) Associated With the Administration of MEC (Moderately Emetogenic Chemotherapy)Status unknownNCT01662687Phase 4
• BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered AloneCompletedNCT01662674Phase 1
• Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in Chemotherapy-induced Nausea and Vomiting Associated With the Administration of Highly Emetogenic Chemotherapy (HEC)CompletedNCT01659775Phase 4
• A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic FunctionCompletedNCT01631097Phase 1
• Study to Assess the Effect on Recovery of GI Motility and Safety and to Determine the Optimal Dose of LD02GIFROCompletedNCT01624571Phase 2
• Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.)CompletedNCT01605331Phase 4
• A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid TumorsCompletedNCT01603979Phase 1
• Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C] LC15-0444CompletedNCT01603238Phase 1
• Phase III Trial to Evaluate the Efficacy and Safety of LC15-0444 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 DiabetesCompletedNCT01602003Phase 3
• Phase 3 Trial to Evaluate the Efficacy and Safety of LC15-0444 in Patients With Type 2 DiabetesCompletedNCT01601990Phase 3
• BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 500mg in Comparison to Each Component Administered AloneCompletedNCT01595880Phase 1
• Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive BladderCompletedNCT01578304Phase 4
• Efficacy and Safety of LBSA0103 Versus Hyruan Plus Injection in Patients With Knee OsteoarthritisCompletedNCT01510535Phase 3
• Bioequivalence of LB80380 Free Base and Maleate Salt TabletsCompletedNCT01427868Phase 1
• Pharmacokinetic Drug Interaction Study in Healthy Male SubjectsCompletedNCT01426906Phase 1
• Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of LC15-0444 and Metformin After Oral Administration in Healthy Male SubjectsCompletedNCT01426399Phase 1
• A Phase 1 Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Tivozanib in Healthy SubjectsCompletedNCT01363804Phase 1
• A Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy SubjectsCompletedNCT01363778Phase 1
• Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189CompletedNCT01361646Phase 1
• Pharmacokinetics and Safety Study of Apetrol ES in Healthy Male VolunteersCompletedNCT01342055Phase 1
• A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Tivozanib (AV-951) in Healthy SubjectsCompletedNCT01316848Phase 1
• A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid TumorsCompletedNCT01306630Phase 1
• Immunogenicity and Safety Study of 4th LBVH0101 After the Primary Vaccination in LG-VHCL002 StudyCompletedNCT01251133Phase 3
• Long-term Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis BStatus unknownNCT01242787Phase 2
• A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid TumorsCompletedNCT01210846Phase 1
• Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25 mg With Those of Enbrel®CompletedNCT01145950Phase 1
• Efficacy and Safety of Lercanidipine and Valsartan in Patients With Essential HypertensionCompletedNCT01122251Phase 2
• A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung CancerCompletedNCT01039948Phase 1/2
• Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis BCompletedNCT01026610Phase 2
• Immunogenicity and Safety Study of LBVH0101 in Healthy Infants at Two, Four and Six Months of AgeCompletedNCT01019772Phase 3
• Pharmacokinetic Drug Interaction Between LC15-0444 and Pioglitazone After Oral Administration in Healthy Male SubjectsCompletedNCT01001013Phase 1
• A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver MetastasesCompletedNCT00969410Phase 1
• Safety and Efficacy Study of LB80380 in the Patients With Lamivudine-Refractory Chronic Hepatitis BCompletedNCT00895596Phase 1/2
• An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00826878Phase 1
• A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple MyelomaCompletedNCT00725634Phase 1
• A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast CancerCompletedNCT00717340Phase 1
• Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal CancersCompletedNCT00660153Phase 1
• Treatment of Adults With Growth Hormone DeficiencyCompletedNCT00596037Phase 3
• A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell CarcinomaCompletedNCT00563147Phase 1
• A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor PatientsCompletedNCT00551850Phase 1
• Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor MalignanciesTerminatedNCT00381654Phase 1
• Treatment of Adults With Growth Hormone DeficiencyCompletedNCT00294619Phase 3
• Treatment of Children With Insufficient Secretion of Growth HormoneStatus unknownNCT00271518Phase 3

← LG Chem overview and focus areas